Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease

Chronic Graft vs Host Disease Clinical Trial

— GVHD-TReG  

Official title:

A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in Patients Who do Not Obtain Complete Remission With Ruxolitinib

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03683498
• Other study ID #: GVHD-TReG
• Status: Completed
• Phase: Phase 1
• Start date: September 25, 2018
• Est. completion date: March 24, 2022

Study information

• Verified date: May 2022
• Source: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib

Description:

The study design is based on a phase I trial in Spanish.

A number of 16 patients will be included to assess the safety and maximum tolerated dose-level of donor regulatory enriched T cell (Treg) in steroid-refractory chronic graft versus host disease (cGVHD) patients who did not obtain complete remission under treatment with ruxolitinib.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: March 24, 2022
• Est. primary completion date: March 24, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Recipient of allogeneic hematopoietic stem cell transplantation.

• Participants must have steroid-refractory cGVHD and had obtained a partial response after at least 4 weeks of treatment with ruxolitinib.

• Steroid-refractory cGVHD is defined as having persistent signs and symptoms of cGVHD (Appendix D) despite the use of prednisone at =0.25 mg/kg/day (or 0.5 mg/kg every other day) for at least 4 weeks (or equivalent dosing of alternate glucocorticoids) without complete resolution of signs and symptoms.

• Stable dose of glucocorticoids for 4 weeks prior to enrolment

• No addition or subtraction of other immunosuppressive medications (e.g., calcineurin-inhibitors, sirolimus, mycophenolate-mofetil) for 4weeks prior to enrolment. The dose of immunosuppressive medicines may be adjusted based on the therapeutic range of that drug

• No age limit. In the case of children participating in the study, the informed consent will be signed by a parents or legal guardians

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Participants must have adequate organ function

• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately

• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Ongoing prednisone requirement >1 mg/kg/day (or equivalent).

• Concurrent use of calcineurin-inhibitor plus sirolimus (either agent alone is acceptable).

• History of thrombotic microangiopathy, hemolytic-uremic syndrome or thrombotic thrombocytopenic purpura.

• New immunosuppressive medication in the 4 weeks prior.

• Extra-corporeal Photopheresis or rituximab therapy in the 4 weeks prior.

• Post-transplant exposure to T-cell or Interleukin-2 targeted medication (e.g. alemtuzumab, basiliximab, denileukin diftitox) within 100 days prior.

• Donor lymphocyte infusion within 100 days prior.

• Active malignant relapse.

• Active uncontrolled infection.

• Organ transplant (allograft) recipient.

• HIV-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with the agents used after allogeneic hematopoietic stem cell transplant (HSCT). In addition, these individuals are at increased risk of lethal infections. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.

• Individuals with active uncontrolled hepatitis B or C are ineligible as they are at high risk of lethal treatment-related hepatotoxicity after hematopoietic stem cell transplant (HSCT).

• Other investigational drugs within 4 weeks prior to enrolment, unless cleared by the Principal Investigator.

• Pregnant women are excluded from this study.

Related Conditions & MeSH terms

• Chronic Graft vs Host Disease
• Graft vs Host Disease

Intervention

Biological:
• Regulatory T-cell enriched infusion
Enrichment of CD25hi regulatory T cells from CD8 and/or CD19 pre-depleted leukapheresis products.

Locations

Country	Name	City	State
Spain	Hospital Universitario Virgen del Rocío	Sevilla	Seville

Sponsors (1)

Lead Sponsor	Collaborator
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Toxicity and maximum tolerated dose	To determine the maximum tolerated dose (MTD) and toxicity of Treg-enriched infusion among patients receiving ruxolitinib.	Up 12 weeks after infusion
Secondary	Quantification of targeted cells of manufacturing Treg-enriched product meeting the targeted cell dose-level.	Percentage of cells viability, negative gram stain/endotoxin, percentage of CD4+CD25+ cells and CD4+CD25+CD127- Treg in order to consider for the infusion.	Before 24 hours to infusion up infusion day
Secondary	Clinical response of Treg-enriched infusion	Each participant should be assigned one of the following categories: 1) complete cGVHD response per NIH criteria, 2) partial cGVHD response per NIH criteria, 3) non-response (includes stable disease) per NIH criteria, 4) progressive cGVHD per NIH criteria, 5) malignant disease relapse, or 6) unknown (not assessable, insufficient data).	Up 12 weeks after Treg infusion
Secondary	Immunologic effects through phenotypical evaluation	Phenotypical evaluation of T cell populations (CD4, CD8, Treg), B and NK cells nuclear cells of Treg-enriched infusion among patients receiving ruxolitinib.	Up 12 weeks after Treg infusion
Secondary	Immunologic effects through immune globulins.	Quantitative immune globulins of Treg-enriched infusion among patients receiving ruxolitinib	Up 12 weeks after Treg infusion
Secondary	Immunologic effects through plasma banking	Plasma banking of Treg-enriched infusion among patients receiving ruxolitinib	Up 12 weeks after Treg infusion
Secondary	Immunologic effects through additional mononuclear cells.	Storage of additional mononuclear cells of Treg-enriched infusion among patients receiving ruxolitinib	Up 12 weeks after Treg infusion
Secondary	Survival after one year of Treg infusion	Number of patients alive after one year of Treg infusion	1 year after Treg infusion